Taysha Gene Therapies
TSHA
65 hedge funds and large institutions have $215M invested in Taysha Gene Therapies in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
35% more funds holding
Funds holding: 48 → 65 (+17)
2.53% less ownership
Funds ownership: 50.63% → 48.1% (-2.5%)
40% less capital invested
Capital invested by funds: $362M → $215M (-$146M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.12M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.69M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 4 |
Two Sigma Investments
New York
|
+$1.04M |
| 5 |
Millennium Management
New York
|
+$906K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$5.97M |
| 3 |
JP Morgan Chase
New York
|
-$2.76M |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
-$831K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$745K |
TSHA Hedge Fund Activity: Q4 2021 in Review
65 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2021, worth a combined $215M — down 40% from $362M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TSHA positions and 5 closed out — a net gain of 17 holders — while 23 added to existing stakes and 8 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $3.12M. The largest seller was Fidelity Investments, cutting an estimated $22.3M.
- 65 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2021, up from 48 in Q3 2021.
- Funds reported $215M of Taysha Gene Therapies stock for Q4 2021, down 40% quarter-over-quarter.
- 22 funds opened new Taysha Gene Therapies positions in Q4 2021 and 5 closed out, a net change of +17 holders.
- The largest Taysha Gene Therapies buyer in Q4 2021 was Nantahala Capital Management, an estimated $3.12M added.
- The largest Taysha Gene Therapies seller in Q4 2021 was Fidelity Investments, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2021.